Recent evidence suggests that major immune antitumor responses are driven by T CD4 and T CD8 cell reactivity against two classes of tumor-derived antigens: neoantigens and cancer germline antigen genes (CAGs) [6]. The gene discussed is CD8A; the disease is cancer.